II. Indications
- Prostate Cancer (Hormone-refractory, metastatic)
III. Contraindications
- Impaired Hepatic Function
- QTc Prolongation
IV. Mechanism
- See Mitotic Inhibitor Chemotherapy
- Cabazitaxel is a taxane Antimitotic Agent with Antineoplastic Agent
- Semi-synthetic derivative of the natural taxoid, 10-deacetylbaccatin 3
- Cabazitaxel binds tubulin
- Inhibits microtubule depolymerization
- Inhibits cell division, arresting the Cell Cycle in G2/M phase
- Inhibits tumor cell proliferation
- Cabazitaxel is unique among Taxanes
- Binds poorly to the P-Glycoprotein efflux pump (potential activity against mutidrug resistant tumors)
- Penetrates the blood brain barrier
V. Medications
- Cabazitaxel Intravenous Solution: 60 mg in 1.5 ml vial (dilute in 5.7 ml supplied diluent)
VI. Dosing
- See other references for disease specific dosing protocols
-
Prostate Cancer (Hormone-refractory, metastatic)
- Cabazitaxel 25 mg/m2 IV every 3 weeks AND
- Prednisone 10 mg orally daily for entire treatment course
- Premedicate each dose (30 minutes prior)
- Dexamethasone 8 mg or equivalent AND
- Antihistamine and H2 Blocker
VII. Adverse Effects
- Myelosuppression (Bone Marrow Suppression)
- Neutropenia (severe)
- Hypersensitivity Reaction (severe)
- Diarrhea (severe)
- Pulmonary effects
VIII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters)
- Use reliable Contraception
- Monitoring
IX. Resources
Images: Related links to external sites (from Bing)
Related Studies
| Definition (NCI_NCI-GLOSS) | A drug used with prednisone to treat hormone-resistant prostate cancer that has spread and that had been treated with docetaxel. It is also being studied in the treatment of other types of cancer. Cabazitaxel blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. |
| Definition (NCI) | A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB). |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C552428 |
| SnomedCT | 447182009, 446706007 |
| English | 1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate], CABAZITAXEL, Cabazitaxel (product), Cabazitaxel, Cabazitaxel (substance), cabazitaxel, 4-acetoxy-13-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate |
| Spanish | cabazitaxel (producto), cabazitaxel, cabazitaxel (sustancia) |
